Modakafusp alfa exhibits direct antiproliferative activity against multiple myeloma (MM) cancer cells in vitro and induces potent and durable antitumor responses in MM xenograft tumor models; it also elicits immunomodulatory and antitumor responses when combined with anti-PD-1 antibodies in mice, with favorable tolerability.